21-Deoxycortisone: A Novel Sensitive and Specific Newborn Screening Marker for Congenital Adrenal Hyperplasia
International Journal of Neonatal Screening · 27.04.2026 · 12 (2) · 27
DOI: 10.3390/ijns12020027 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Neonatal Screening, online erschienen am 27.04.2026. Verfasst von Mark de Hora und 4 weiteren Autor:innen. Beteiligte Einrichtung: LabPlus, Auckland City Hospital, Auckland 1140, New Zealand. Die Arbeit nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Auckland Hospital Medical research Fund, Australia and New Zealand Society of Paediatric Endocrinology and Diabetes, Auckland Medical Research Foundation.
Abstract (Originalsprache)
21-deoxycortisol is a sensitive and specific blood marker for congenital adrenal hyperplasia (CAH). We postulated that 21-deoxycortisone, the 11β-hydroxysteroid dehydrogenase metabolite of 21-deoxycortisol, may also be an accurate bloodspot marker of CAH. Measurement of 21-deoxycortisone was performed on 42 residual NBS specimens with a true positive result for CAH, 11 with a false negative result, and 439 specimens with a false positive result. For this study, the test was considered positive if 21-deoxycortisone was detected. The sensitivity and specificity of 21-deoxycortisone as a marker for classical CAH was calculated and compared to 21-deoxycortisol data from a previous New Zealand study. The method for 21-deoxycortisone measurement was linear to 1000 nmol/L and precision was 7.3–10.3%. The lower limit of quantification was 2 nmol/L, and recovery was 99%. 21-deoxycortisone was ≥2 nmol/L in all 42 true positive samples and in 10 false negative samples, and was not detected in the false positive group of specimens. The sensitivity of 21-deoxycortisone was 98.1%, and specificity was 100%. In a previous study, the sensitivity of 21-deoxycortisol was 88.7% and specificity was 99.8% in 1910 newborn screening tests carried out between 2018 and 2021. Incorporating 21-deoxycortisone into a second-tier test and adjustment of primary screening protocols could improve the accuracy of newborn screening for CAH. Longer term prospective studies on the performance of 21-deoxycortisone are warranted.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- LabPlus, Auckland City Hospital, Auckland 1140, New Zealand.
- Liggins' Institute, University of Auckland, Auckland 1142, New Zealand.
ORCID-Profile: Mark de Hora, Natasha Heather
Förderung
- Auckland Hospital Medical research Fund
- Australia and New Zealand Society of Paediatric Endocrinology and Diabetes
- Auckland Medical Research Foundation
Zitieren
APA
de Hora, M., Heather, N., Webster, D., Albert, B. B., & Hofman, P. (2026). 21-Deoxycortisone: A Novel Sensitive and Specific Newborn Screening Marker for Congenital Adrenal Hyperplasia. International Journal of Neonatal Screening, 12(2), 27. https://doi.org/10.3390/ijns12020027
Vancouver
de Hora M, Heather N, Webster D, Albert BB, Hofman P. 21-Deoxycortisone: A Novel Sensitive and Specific Newborn Screening Marker for Congenital Adrenal Hyperplasia. International Journal of Neonatal Screening. 2026;12(2):27. doi:10.3390/ijns12020027
BibTeX
@article{deHora2026,
author = {de Hora, Mark and Heather, Natasha and Webster, Dianne and Albert, Benjamin B and Hofman, Paul},
title = {21-Deoxycortisone: A Novel Sensitive and Specific Newborn Screening Marker for Congenital Adrenal Hyperplasia},
journal = {International Journal of Neonatal Screening},
year = {2026},
volume = {12},
number = {2},
pages = {27},
doi = {10.3390/ijns12020027}
}
EUVIMED